NCT01968902View on ClinicalTrials.gov

Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

January 27, 2016

Study Completion Date

December 31, 2016

Conditions
Muscle SpasticityMultiple Sclerosis
Interventions
BIOLOGICAL

incabotulinumtoxinA

A dose of 200 units to 400 units of Xeomin will be injected by EMG-guided technique into the appropriate muscles in the effected leg at injection visit

BIOLOGICAL

Placebo

Saline injection on the day of injection visit

Trial Locations (1)

12110

Multiple Sclerosis Center of Northeastern New York, Latham

All Listed Sponsors
collaborator

Merz North America, Inc.

INDUSTRY

lead

Multiple Sclerosis Center of Northeastern New York

OTHER

NCT01968902 - Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients | Biotech Hunter | Biotech Hunter